NOTICE: When government or other drawings, specifications or other data are used for any purpose other than in connection with a definitely related government procurement operation, the U. S. Government thereby incurs no responsibility, nor any obligation whatsoever; and the fact that the Government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use or sell any patented invention that may in any way be related thereto.
Differential response to allogenic and xenogenic skin grafts by sublethally irradiated (670 rad) and non-irradiated mice sensitized by various means

By L. L. Tyan
L. J. Cole

U.S. NAVAL RADILOGICAL DEFENSE LABORATORY
SAN FRANCISCO 24, CALIFORNIA

402 294

CATALOGED BY ASTIA AS AD No. 402294

11 March 1963

USNRDL-TR-628

APR 29, 1963
EXPERIMENTAL PATHOLOGY BRANCH
L. J. Cole, Head

BIOLOGICAL AND MEDICAL SCIENCES DIVISION
E. L. Alpen, Head

ADMINISTRATIVE INFORMATION

This work was accomplished under the Bureau of Medicine and Surgery Task MAR06-08-S200, Subtask 3, Technical Objective AW-6, as described in the U. S. Naval Radiological Defense Laboratory Annual Report to the Bureau of Medicine and Surgery (OPNAV FORM 3910-1) of 31 December 1962, and is listed in the U. S. Naval Radiological Defense Laboratory Technical Program Summary for Fiscal Years 1963-1965 of 1 November 1962 under Program A3, Problem 2, entitled "Nuclear Warfare Aspects of Whole Body Ionizing Radiation." This study was supported through funds provided by the Bureau of Medicine and Surgery, and the Defense Atomic Support Agency under NWIR Program A4c, Subtask 03.027.
Twelve to 14 week old female LAF₁ mice were pre-sensitized either with 3 i.p. injections of BALB/c or rat spleen or skin cells, or by means of two consecutive BALB/c or rat skin tail grafts. One week following the last injection or the rejection of the second skin graft, the mice either were grafted with LAF₁, BALB/c, C3D/2 and rat skin or they received 670 rad whole body X radiation and were grafted immediately thereafter. The data indicate that skin grafts induce a more vigorous and more radioresistant "second-set" response than do dissociated cells. Pre-sensitization with allogenic spleen cells resulted in prolonged survival of subsequent allogenic skin grafts in sublethally irradiated mice. The second-set response to a xenogenic skin graft was found to be more radioresistant than was that to an allogenic graft. The converse was true with regard to the first-set response.
SUMMARY

The Problem:

It is generally accepted that any tissue possesses antigens capable of sensitizing a non-related animal to subsequent skin grafts from the original tissue donor. However, it is also apparent that sensitization with a skin graft produces a more vigorous and persistent sensitivity than does immunization by any other means. Presented are data contrasting, in non-irradiated and sublethally irradiated mice, the degree of sensitization to subsequent skin grafts induced by the intraperitoneal injection of spleen cells or dissociated-skin cells, allogenic (another strain of mouse) or xenogenic (another species), with that produced by skin grafts.

The Findings:

Twelve to 14 week old female LAF1 mice were pre-sensitized either with 3 i.p. injections of BALB/c or rat spleen or skin cells, or by means of two consecutive BALB/c or rat skin tail grafts. One week following the last injection or the rejection of the second skin graft, the mice either were grafted with LAF1, BALB/c, C3D/2 and rat skin or they received 670 rad whole body X radiation and were grafted immediately thereafter. The data indicate that skin grafts induce a more vigorous and more radioresistant "second-set" response than do dissociated cells. Pre-sensitization with allogenic spleen cells resulted in prolonged survival of subsequent allogenic skin grafts in
sublethally irradiated mice. The second-set response to a xenogenic skin graft was found to be more radioresistant than was that to an allogenic graft. The converse was true with regard to the first-set response.
INTRODUCTION

It is generally accepted that any nucleated cell, regardless of tissue origin, possesses transplantation isoantigens capable of eliciting specific "homograft sensitivity" (1,2). However, if "homograft sensitivity" is induced by means other than the transplantation of living tissue grafts, the route of administration, amount of isoantigen and schedule of immunization assume prime importance with respect to the results achieved (3-6). In general, sensitization by means of a foreign skin graft produces a more vigorous and persistent "homograft sensitivity" than does sensitization by means of dissociated cells of any type, administered by any route.

In specific instances, "hyperimmunization" with dissociated lymphoid cells or by the intravenous administration of dissociated epidermal cells has resulted in prolonged survival of subsequent specifically related skin grafts (4,6). For more specific detail with regard to this complex subject the reader is referred to the excellent papers cited and to reviews by Lawrence (8), Snell (9) and Brent (10).

Presented below are data contrasting the responses to subsequent allogenic and xenogenic skin grafts by sublethally X irradiated and non-irradiated mice previously sensitized with allogenic or xenogenic skin grafts or with dissociated cell preparations. It will be demonstrated that the degree of sensitization produced by means of dissociated cells (with the methods used) is both less pronounced and
more "radiosensitive" than is that produced with skin grafts. Further, the "homograft sensitivity" induced by xenogenic dissociated skin and spleen cells will be shown to be more vigorous and less "radiosensitive" than that produced with similar preparations of allogenic tissues. It will be apparent the second-set response to a xenogenic skin graft is more radioresistant than is the second-set response to an allogenic graft ([11]). The converse will be shown to be true with regard to the first-set response.

MATERIALS AND METHODS

Twelve to 14 week old female \((C57L \times A)F_1\), \((LAF_1)\) mice were used as skin graft recipients. Skin graft donors were adult female \(LAF_1\) \((H2\ a\ b)\), male \(BALB/c\ \((H2\ d)\) and \((C3H \times DBA/2)F_1\), \((C3D/2)\), \((H2\ Kd)\) mice, and 2-3 week old male and female Sprague-Dawley rats. The orthotopic tail skin grafting method of Bailey and Usoma was used ([12]). Details of grafting and the criteria of rejection (total destruction of the engrafted tissue) have been reported previously ([11]). Mean survival time of the grafts and standard deviation (S.D.) are reported.

Dissociated spleen cells were prepared from the spleens of adult male \(BALB/c\) mice and adult female Sprague-Dawley rats. The spleens were removed aseptically and lightly homogenized in cold Tyrode's solution. Dissociated skin cells were prepared from skin removed from the ears of male \(BALB/c\) mice or from the tails of 2-3 week old male and female Sprague-Dawley rats. The skin was trimmed of all fat or
cartilage, weighed, and gently but thoroughly homogenized in cold Tyrode's solution. Initially each mouse received the equivalent of 1/5 BALB/c spleen (approx. 20 mg) or 1/20 rat spleen (approx. 30 mg) per injection, but when a direct comparison was being made with dissociated skin cells as an antigenic source, wet weight of the splenic tissue or skin was the measure (22 mg or 50 mg). The mice were sensitized to BALB/c or rat skin with two consecutive skin grafts, or to dissociated spleen or skin cells by means of 3 intraperitoneal injections of the respective homogenate within 9 days.

One week following the rejection of the second skin graft or the last injection of dissociated skin or spleen cells, the mice either were grafted with LAF₁, BALB/c, C3D/2 and rat skin, or they received 670 rad whole body X radiation (LD 5) and were grafted within 6 hours thereafter. The radiation factors (250 KVP, 15 ma; HVL 1.5 mm Cu; 30 rad/min) and details of exposure were the same as previously reported from this Laboratory (13). Norms were obtained for first and second-set responses of non-irradiated LAF₁ mice to (1) BALB/c skin grafts alone, (2) rat skin grafts alone and (3) BALB/c, C3D/2 and rat skin grafts. As controls, non-sensitized mice received 670 rad whole body X radiation and were grafted with LAF₁, BALB/c, C3D/2 and rat skin within 6 hours thereafter.

In order to compare the degree of sensitization induced by dissociated skin or spleen cells, allogenic or xenogenic, groups of
mice received, within 9 days, 3 intraperitoneal injections of the respective homogenate (22 mg or 50 mg wet weight of tissue per injection). One week following the last injection, they either were grafted or they received 670 rad whole body X radiation and were grafted as described above.

Certain groups of mice were regrafted 90 days after the original full set of grafts were in place. This was done in an effort to determine if the original method of sensitization (if any) and/or the subsequent irradiation (if any) would influence or modify the degree of sensitization induced by the test grafts.

All mice were housed 10 per cage. The diet was Purina Lab Chow, and water containing 1% Neomycin was given ad lib.

RESULTS

Non-Irradiated Mice Table I.

Non-irradiated LAF mice rejected first-set BALB/c skin grafts in 12.6 ± 0.8 days and second-set grafts in 6.1 ± 1.2 days. First-set rat skin grafts were rejected in 7.6 ± 0.7 days and second-set grafts in 4.4 ± 0.6 days. When a full set of grafts (LAF, BALB/c, C3D/2 and rat) were placed on non-sensitized mice there was a slight acceleration of the first-set response to the allogenic grafts (10.1 ± 1.6 days), but no effect was noted on the rejection time of the rat grafts. The second-set response to a full set of grafts was essentially that seen when each graft was tested separately. Mice pre-sensitized with BALB/c
TABLE I

REJECTION OF ALLOGENIC AND XENOCENIC SKIN GRAFTS BY LAF1 MICE PREVIOUSLY SENSITIZED WITH SKIN GRAFTS OR DISSOCIATED SPLEEN CELLS

<table>
<thead>
<tr>
<th>ORIGINAL MEANS OF SENSITIZATION</th>
<th>PRIOR GRAFTS OR AMT. OF SPLEEN</th>
<th>NUMBER OF MICE</th>
<th>ISOGRAPHS REJECTED</th>
<th>TIME OF COMPLETE REJECTION MEAN SURVIVAL (days) ± S.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td></td>
<td>33</td>
<td></td>
<td>12.5 ± 0.8</td>
</tr>
<tr>
<td>None</td>
<td>1</td>
<td>38</td>
<td></td>
<td>5.1 ± 1.2</td>
</tr>
<tr>
<td>None</td>
<td>30</td>
<td>10</td>
<td>0</td>
<td>10.1 ± 1.6</td>
</tr>
<tr>
<td>None</td>
<td>1(full set)</td>
<td>10</td>
<td>0</td>
<td>7.1 ± 0.3</td>
</tr>
<tr>
<td>BALB/c skin graft</td>
<td>2</td>
<td>10</td>
<td>0</td>
<td>7.1 ± 1.0</td>
</tr>
<tr>
<td>BALB/c spleen cells</td>
<td>22 mg x 3*</td>
<td>14</td>
<td>0</td>
<td>11.4 ± 2.6</td>
</tr>
<tr>
<td>None</td>
<td></td>
<td>28</td>
<td></td>
<td>7.6 ± 0.7</td>
</tr>
<tr>
<td>None</td>
<td>1</td>
<td>29</td>
<td></td>
<td>4.4 ± 0.6</td>
</tr>
<tr>
<td>Rat skin graft</td>
<td>2</td>
<td>18</td>
<td>0</td>
<td>9.0 ± 1.0</td>
</tr>
<tr>
<td>Rat spleen cells</td>
<td>22 mg x 3</td>
<td>9</td>
<td>0</td>
<td>10.5 ± 1.8</td>
</tr>
<tr>
<td>Rat spleen cells</td>
<td>1/20 x 3</td>
<td>11</td>
<td>0</td>
<td>9.9 ± 1.4</td>
</tr>
</tbody>
</table>

1Orthotopic tail skin grafts, single or multiple, were placed on 12-14 week old female LAF1 mice. Tail skin donors were BALB/c and C3H/2 adult male mice, 2-3 week old male and female Sprague-Dawley rats. Unless specified, the mice were pre-sensitized either with two consecutive allogenic or xenogenic skin grafts or 3 i.p. injections (within 9 days) of an homogenate of rat or BALB/c spleen cells. One week following the last injection of spleen cells or the rejection of the second skin graft, the mice were grafted with LAF1, BALB/c, C3H/2 and rat skin.

*Wet weight.
skin grafts rejected subsequent BALB/c and C3D/2 grafts in a normal second-set manner, while rat skin grafts were rejected as first-set grafts. However, mice pre-sensitized with BALB/c dissociated spleen cells (22 mg or 50 mg) rejected the allogenic skin grafts as if they were first-set, i.e., there was no evidence of accelerated rejection (Table I and III).

Mice previously sensitized with rat skin grafts rejected their allogenic skin grafts (first-set) in an accelerated manner (9.0 ± 1.0 days). (A previous report (11) has shown that no common transplantation antigens are shared between rat skin and BALB/c or C3D/2 bone marrow cells.) However, pre-sensitization with rat spleen cells produced not only a less vigorous "second-set" response to rat skin grafts (5.0-5.2 versus 3.6-4.4), but little or no effect upon the rejection of first-set allogenic grafts (Table I and III). Moreover, in one instance (Table I), sensitization with rat spleen cells produced a slight prolongation of survival of first-set rat grafts (8.4 ± 0.9 days).

Sublethally Irradiated (670 rad) Mice Table II.

A significant number of sublethally irradiated mice previously sensitized with BALB/c skin grafts rejected subsequent allogenic grafts appreciably sooner than did the control group. While one group of mice differed only slightly from the controls, 50% of a second group rejected their allogenic grafts between the seventh and ninth post-irradiation days. However, mice pre-sensitized with BALB/c spleen cells had great
TABLE II

REJECTION OF ALLOGENIC AND XENOGENIC SKIN GRAFTS BY SUBLETHALLY IRRADIATED (670 RAD) LAF₁ MICE PREVIOUSLY SENSITIZED WITH SKIN GRAFTS OR DISSOCIATED SPLEEN CELLS

<table>
<thead>
<tr>
<th>MEANS OF SENSITIZATION</th>
<th>PRIOR GRAFTS OR</th>
<th>NUMBER OF MICE</th>
<th>ISOGRAFTS</th>
<th>TIME OF COMPLETE REJECTION</th>
<th>MEAN SURVIVAL (days) ± S.D.</th>
<th>BALB/c</th>
<th>C3D/2</th>
<th>RAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BALB/c skin grafts</td>
<td>2</td>
<td>6</td>
<td>0</td>
<td>18.3 ± 3.1**</td>
<td>18.2 ± 4.4</td>
<td>22.1 ± 2.2</td>
<td>21.8 ± 2.8</td>
<td></td>
</tr>
<tr>
<td>BALB/c skin grafts</td>
<td>2</td>
<td>10</td>
<td>1</td>
<td>10.7 ± 3.4</td>
<td>10.8 ± 3.1*</td>
<td>24.4 ± 2.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BALB/c spleen cells</td>
<td>1/5 x 3</td>
<td>19</td>
<td>0</td>
<td>28.0 ± 5.7</td>
<td>28.8 ± 5.1</td>
<td>21.8 ± 2.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat skin grafts</td>
<td>2</td>
<td>7</td>
<td>1</td>
<td>22.1 ± 3.0</td>
<td>22.2 ± 3.0</td>
<td>7.0 ± 1.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat skin grafts</td>
<td>2</td>
<td>10</td>
<td>1</td>
<td>15.4 ± 4.3</td>
<td>11.4 ± 4.9</td>
<td>4.4 ± 0.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat skin grafts</td>
<td>2</td>
<td>9</td>
<td>0</td>
<td>20.5 ± 8.7</td>
<td>18.3 ± 8.0</td>
<td>3.6 ± 0.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat spleen cells</td>
<td>1/20 x 3</td>
<td>9</td>
<td>1</td>
<td>27.6 ± 8.0</td>
<td>27.4 ± 7.0</td>
<td>10.5 ± 4.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat spleen cells</td>
<td>1/20 x 3</td>
<td>10</td>
<td>1</td>
<td>21.3 ± 5.2</td>
<td>21.8 ± 8.4</td>
<td>12.2 ± 4.8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*One week following the last injection of spleen cells or the rejection of the second skin graft, the mice received 670 rad whole body X radiation and were grafted with LAF₁, BALB/c, C3D/2 and Rat skin within 6 hours, thereafter.

**5/10 BALB/c grafts rejected between 7-9 days.

*5/9 C3D/2 grafts rejected between 7-9 days.
difficulty rejecting their allogenic grafts (Tables II and III). All three groups, so treated, showed significant prolongation of allogenic graft survival as compared to the controls. In only one instance, in a group of 4 mice pre-sensitized with BALB/c spleen cells, was the rejection of the rat grafts delayed (Table III).

Two of three groups of mice, previously sensitized with rat skin grafts and sublethally irradiated, rejected subsequent rat grafts in a normal second-set manner. In the third group, rejection of the rat grafts was slightly delayed (7.0 ± 1.4 days). One group of mice, so treated, rejected concurrent allogenic grafts significantly sooner than did the control group. While mice sensitized with rat spleen cells did reject subsequent rat grafts decidedly sooner than did the controls, the response, which seemed to be dependent upon the amount of antigen given, was neither as vigorous nor as rapid as that seen in mice sensitized with skin grafts (Tables II and III). Moreover, there was little or no effect upon allogenic graft survival (if anything, a slight prolongation of survival).

It should be noted that the first-set response to allogenic skin grafts recovered from the effects of sublethal irradiation significantly sooner than did the first-set response to a xenogenic skin graft.

Dissociated Skin and Spleen Cells Table III.

The rejection of allogenic and xenogenic skin grafts by sublethally irradiated and non-irradiated LAF mice previously sensitized with dissociated spleen cells, BALB/c or rat, has been described above.
TABLE III
REJECTION OF ALLOGENIC AND XENOGENIC SKIN GRAFTS BY
NON-IRRADIATED AND SUBLETHALLY IRRADIATED (670 RAD) LAF1 MICE
PREVIOUSLY SENSITIZED WITH DISSOCIATED SKIN OR SPLEEN CELLS*

<table>
<thead>
<tr>
<th>MEANS OF SENSITIZATION</th>
<th>WET WT.</th>
<th>NO. OF RADS</th>
<th>NO. OF MICE</th>
<th>ISOGRAFTS REJECTED</th>
<th>TIME OF COMPLETE REJECTION</th>
<th>MEAN SURVIVAL(days) ± S.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BALB/c</td>
<td>C3D/2</td>
</tr>
<tr>
<td>None</td>
<td>None</td>
<td>670</td>
<td>30</td>
<td>0</td>
<td>10.1 ± 1.6</td>
<td>10.1 ± 1.5</td>
</tr>
<tr>
<td>BALB/c spleen cells</td>
<td>22 mg x 3</td>
<td>21</td>
<td>2</td>
<td>11.4 ± 2.8</td>
<td>20.3 ± 4.0</td>
<td>26.0 ± 4.6</td>
</tr>
<tr>
<td>BALB/c spleen cells</td>
<td>50 mg x 3</td>
<td>670</td>
<td>10</td>
<td>0</td>
<td>10.4 ± 2.0</td>
<td>20.6 ± 2.3</td>
</tr>
<tr>
<td>BALB/c spleen cells</td>
<td>50 mg x 3</td>
<td>670</td>
<td>4</td>
<td>0</td>
<td>30.5 ± 1.1</td>
<td>29.6 ± 2.3</td>
</tr>
<tr>
<td>BALB/c skin cells</td>
<td>22 mg x 3</td>
<td>670</td>
<td>5</td>
<td>0</td>
<td>23.0 ± 9.4*</td>
<td>17.5 ± 9.8#</td>
</tr>
<tr>
<td>BALB/c skin cells</td>
<td>50 mg x 3</td>
<td>670</td>
<td>10</td>
<td>0</td>
<td>8.6 ± 1.8</td>
<td>7.2 ± 0.7</td>
</tr>
<tr>
<td>BALB/c skin cells</td>
<td>670</td>
<td>9</td>
<td>0</td>
<td>21.1 ± 4.1</td>
<td>20.3 ± 4.1</td>
<td>27.5 ± 1.5</td>
</tr>
<tr>
<td>Rat spleen cells</td>
<td>22 mg x 3</td>
<td>670</td>
<td>9</td>
<td>0</td>
<td>10.5 ± 1.8</td>
<td>11.1 ± 1.3</td>
</tr>
<tr>
<td>Rat spleen cells</td>
<td>670</td>
<td>9</td>
<td>0</td>
<td>22.2 ± 3.6</td>
<td>20.1 ± 3.1</td>
<td>16.1 ± 4.6</td>
</tr>
<tr>
<td>Rat spleen cells</td>
<td>50 mg x 3</td>
<td>670</td>
<td>10</td>
<td>0</td>
<td>11.4 ± 1.2</td>
<td>10.3 ± 1.5</td>
</tr>
<tr>
<td>Rat spleen cells</td>
<td>670</td>
<td>9</td>
<td>0</td>
<td>25.0 ± 3.6</td>
<td>24.2 ± 4.5</td>
<td>7.8 ± 0.9</td>
</tr>
<tr>
<td>Rat skin cells</td>
<td>22 mg x 3</td>
<td>670</td>
<td>9</td>
<td>0</td>
<td>18.4 ± 2.5</td>
<td>20.0 ± 2.7</td>
</tr>
<tr>
<td>Rat skin cells</td>
<td>50 mg x 3</td>
<td>670</td>
<td>9</td>
<td>0</td>
<td>10.7 ± 1.5</td>
<td>9.9 ± 2.2</td>
</tr>
<tr>
<td>Rat skin cells</td>
<td>670</td>
<td>8</td>
<td>0</td>
<td>22.7 ± 4.2</td>
<td>19.3 ± 8.0</td>
<td>9.8 ± 4.4</td>
</tr>
</tbody>
</table>

* Mice were sensitized with 3 i.p. injections (within 9 days) of a homogenate of BALB/c or Rat, spleen or skin cells. One week following the last injection, the mice received 670 rad whole body X radiation, and within 6 hours they were grafted with LAF1, BALB/c, C3D/2 and rat skin.
* 2/3 BALB/c grafts rejected at 9 days.
* 1/5 C3D/2 grafts rejected at 9 days.
Non-irradiated mice pre-sensitized with BALB/c dissociated skin cells rejected subsequent allogenic grafts in an apparently normal second-set manner. However, sublethally irradiated mice, so treated, rejected their allogenic grafts at about the same time as did the non-sensitized irradiated controls, i.e., there was no evidence of accelerated rejection or of prolongation of survival. In addition, the survival of rat skin grafts was somewhat prolonged under these conditions.

Non-irradiated mice pre-sensitized with rat skin cells rejected subsequent rat skin grafts with an apparently normal second-set response. However, sublethally irradiated mice pre-sensitized with rat dissociated skin cells (22mg x 3) rejected rat skin grafts at about the same time as did the control group. When the sensitizing dose was increased (50 mg x 3), the irradiated mice rejected the rat grafts in 9.8 ± 4.4 days (about as effective as an equal weight of dissociated spleen cells). In no instance was there an appreciable effect upon allogenic graft survival.

Irradiated and Non-irradiated Mice Regrafted 90 days After Original Full Set of Grafts Table IV.

Irradiated and non-irradiated, "non-pre-sensitized" mice, regrafted 90 days after the original full set of grafts were in place, rejected all grafts somewhat sooner than did non-irradiated mice 20 days after the first set of grafts. Sublethally irradiated mice, pre-sensitized with BALB/c spleen cells and regrafted 90 days after irradiation, rejected
### TABLE IV

**REJECTION OF ALLOGENIC AND XENOCENIC SKIN GRAFTS BY PRE-SENSITIZED AND NON-PRE-SENSITIZED, SUBLETHALLY IRRADIATED (670 RAD) AND NON-IRRADIATED, LAF MICE 90 DAYS AFTER ORIGINAL GRAFTING**

<table>
<thead>
<tr>
<th>Original</th>
<th>Time</th>
<th>Dose</th>
<th>No. of Mice</th>
<th>Iso grafts</th>
<th>Time of Complete Rejection</th>
<th>Mean Survival (days) ± S.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meas of</td>
<td>Meas of</td>
<td>Meas of</td>
<td>1st Set</td>
<td>Rejected</td>
<td>BALB/c</td>
<td>C3H/2</td>
</tr>
<tr>
<td>Sensitization</td>
<td>Sensitization</td>
<td>Sensitization</td>
<td>(rads)</td>
<td>(days)</td>
<td>BALB/c</td>
<td>C3H/2</td>
</tr>
<tr>
<td>None **</td>
<td>None</td>
<td>20</td>
<td>10</td>
<td>0</td>
<td>5.9 ± 2.0</td>
<td>4.3 ± 0.9</td>
</tr>
<tr>
<td>None</td>
<td>None</td>
<td>30</td>
<td>7</td>
<td>0</td>
<td>7.1 ± 0.3</td>
<td>7.0 ± 0.7</td>
</tr>
<tr>
<td>None</td>
<td>None</td>
<td>670</td>
<td>0.2</td>
<td>21</td>
<td>2</td>
<td>21.0 ± 3.5</td>
</tr>
<tr>
<td>None</td>
<td>None</td>
<td>670</td>
<td>90</td>
<td>4</td>
<td>0</td>
<td>5.0 ± 1.1</td>
</tr>
<tr>
<td><strong>BALB/c spleen cells</strong></td>
<td></td>
<td>90</td>
<td>10</td>
<td>1</td>
<td>10.5 ± 2.1</td>
<td>10.5 ± 1.4</td>
</tr>
<tr>
<td><strong>BALB/c spleen cells</strong></td>
<td></td>
<td>670</td>
<td>0.2</td>
<td>10</td>
<td>0</td>
<td>32.5 ± 3.1</td>
</tr>
<tr>
<td>BALB/c spleen cells</td>
<td>BALB/c spleen cells</td>
<td>670</td>
<td>90</td>
<td>10</td>
<td>0</td>
<td>4.7 ± 1.7</td>
</tr>
<tr>
<td><strong>BALB/c skin grafts</strong></td>
<td></td>
<td>90</td>
<td>10</td>
<td>0</td>
<td>7.1 ± 1.1</td>
<td>4.9 ± 1.0</td>
</tr>
<tr>
<td><strong>BALB/c skin grafts</strong></td>
<td></td>
<td>670</td>
<td>0.2</td>
<td>10</td>
<td>1</td>
<td>10.7 ± 3.4</td>
</tr>
<tr>
<td>BALB/c skin grafts</td>
<td>BALB/c skin grafts</td>
<td>670</td>
<td>90</td>
<td>6</td>
<td>0</td>
<td>6.3 ± 3.0</td>
</tr>
<tr>
<td><strong>Rat spleen cells</strong></td>
<td></td>
<td>90</td>
<td>9</td>
<td>0</td>
<td>10.5 ± 1.8</td>
<td>11.1 ± 1.3</td>
</tr>
<tr>
<td><strong>Rat spleen cells</strong></td>
<td></td>
<td>670</td>
<td>0.2</td>
<td>10</td>
<td>1</td>
<td>21.3 ± 5.2</td>
</tr>
<tr>
<td>Rat spleen cells</td>
<td>Rat spleen cells</td>
<td>670</td>
<td>90</td>
<td>9</td>
<td>0</td>
<td>5.9 ± 1.1</td>
</tr>
<tr>
<td><strong>Rat skin grafts</strong></td>
<td></td>
<td>90</td>
<td>9</td>
<td>0</td>
<td>7.0 ± 1.1</td>
<td>6.4 ± 1.4</td>
</tr>
<tr>
<td><strong>Rat skin grafts</strong></td>
<td></td>
<td>670</td>
<td>0.2</td>
<td>10</td>
<td>1</td>
<td>15.4 ± 4.3</td>
</tr>
<tr>
<td>Rat skin grafts</td>
<td>Rat skin grafts</td>
<td>670</td>
<td>90</td>
<td>4</td>
<td>0</td>
<td>7.2 ± 1.2</td>
</tr>
</tbody>
</table>

---

*The mice were regrafted 90 days after the original full set of grafts were in place. Previous means of sensitization (if any) and amount of X radiation (if any) are outlined in the table. The results obtained upon regrafting are paired with the initial results from the same mice.

**Second-set to all grafts.

*Two isografts were rejected at 6 days. All others appeared to be in stage of early rejection between 4th and 6th days.

#All isografts were very inflamed and friable between the 4th and 6th days.
all grafts somewhat sooner than did a similar group which had not been irradiated (4.7 ± 1.7 days versus 6.5 ± 0.7 days). These results held true, generally, for all groups, irradiated and non-irradiated, which were regrafted 90 days after the original full set of grafts. One can conclude, therefore, that neither prior methods of sensitization nor sublethal irradiation interferes materially with the subsequent sensitization induced by means of skin grafts.

During the course of the experiments previously mentioned, it became apparent that, during a vigorous second-set response to allogenic or particularly to xenogenic skin grafts, the concurrent isografts and allografts become markedly reddened and friable. This effect was most prominent during the last series of experiments (regrafting 90 days after the original full set of grafts were in place). In one group of 10 mice (Table IV) two isografts were rejected at 6 days in a manner suggestive of a "homograft response", and the other isografts seemed to be in imminent danger of succumbing to a similar fate. In a second group of nine mice, a similar phenomenon was observed, although no isografts were actually lost; the reddening and friability quickly subsided after the sixth day, i.e., after rejection of the allogenic and xenogenic skin grafts. The reaction appeared to be predominantly vascular in nature, being characterized by petechial hemorrhages, capillary fragility and, at times, frank ecchymoses. The nature of the pathological changes, as observed at the graft sites, strongly suggested either
the presence of a non-specific agent capable of greatly increasing capillary permeability or a deficiency of a factor essential to the maintenance of capillary wall integrity. All surviving isografts were intact and healthy 60 days after being placed. This phenomenon was not observed among the control groups.

DISCUSSION

The foregoing data, derived from non-irradiated and sublethally irradiated mice, indicate that with the methods used dissociated skin or spleen cells induce a "homograft sensitivity" inferior to or perhaps unlike that produced with skin grafts, allogenic or xenogenic. Non-irradiated mice pre-sensitized with allogenic dissociated skin cells or with xenogenic dissociated skin or spleen cells, rejected subsequent skin grafts of the appropriate genotype in an apparently normal second-set manner. By contrast, sublethally irradiated mice, similarly treated, rejected their grafts significantly later than did mice pre-sensitized with skin grafts. Moreover, sublethally irradiated mice pre-sensitized with allogenic spleen cells rejected subsequent allogenic grafts significantly later than did the non-sensitized sublethally irradiated controls. The latter phenomenon suggests "self enhancement" mediated through humoral antibodies (5). In general, sensitization with dissociated rat cells resulted in a more vigorous response to subsequent skin grafts by non-irradiated and sublethally irradiated mice than did sensitization with comparable allogenic tissues.
While it is not possible from these data to clearly distinguish quantitative from qualitative differences in the "homograft sensitivity" induced by the several methods used, the disparity between the degree of sensitivity elicited by dissociated cells and orthotopic skin grafts can hardly be a matter of antigenic dosage, as the total amount of tissue administered with the former method was up to forty times greater than with the latter. One therefore is inclined to believe the "immune system" deals with dissociated cell antigens in a manner qualitatively different from that reserved for solid homografts, i.e., a true "second-set" response is not, as a rule, induced by means of dissociated cells.

A previous report (11) presented data demonstrating, in lethally irradiated, bone-marrow protected mice, the differential radiosensitivity of first and second-set responses to allogenic and xenogenic skin grafts: that is, the second-set response of mice pre-sensitized with allogenic or xenogenic skin grafts was more radioresistant than was the first-set response; the second-set response to a xenogenic skin graft was more radioresistant than was that to an allogenic graft; the converse appeared to be true with regard to the first-set response. The present data in sublethally irradiated mice support and extend these findings. The implications of these observations with regard to the possible heterogeneity of the "immune system" have been discussed previously (11): These data strongly suggest the existence of independent and interdependent "cell lines or systems", each with its own spectrum and potential for reactivity.
The data contained in the present report suggest, further, that "sensitivity" induced by means other than skin grafts is the manifestation of a mechanism qualitatively different from the classic second-set response.

SUMMARY

1. Data are presented demonstrating in sublethally X-irradiated (670 rad) mice the differential radiosensitivity of the first and second-set responses to allogenic (H-2 difference) and xenogenic (rat) skin grafts: The second-set response is more radioresistant than is the first-set response; the second-set response to a xenogenic skin graft is more radioresistant than is that to an allogenic graft; the converse is true with regard to the first-set response.

2. The "homograft sensitivity" induced with xenogenic or allogenic dissociated skin or spleen cells (with the methods used) appears to be "inferior" to or unlike that induced with skin grafts. Sensitization with xenogenic dissociated cells resulted in a more vigorous response (i.e., shorter rejection time) to subsequent appropriate grafts in both non-irradiated and sublethally irradiated mice than did sensitization with comparable allogenic tissues.

3. Allogenic skin grafts survived significantly longer on sublethally irradiated mice, pre-sensitized with allogenic dissociated spleen cells than they did on the appropriate controls. By contrast, pre-sensitization with allogenic dissociated skin cells had essentially no effect on allogenic graft survival in sublethally irradiated mice.
4. Non-irradiated and sublethally irradiated (670 rad) mice previously sensitized with rat skin grafts rejected subsequent first-set allogenic grafts significantly sooner than did their appropriate controls. This effect was not seen when the mice had been previously sensitized with dissociated rat skin or spleen cells.

5. Neither the initial method of sensitization nor sublethal irradiation influenced the sensitization induced by subsequent skin grafts.

6. Certain observations made during the accelerated rejection of allogenic and particularly of xenogenic skin grafts suggested either the presence of a non-specific agent capable of disrupting the capillary bed at the graft sites or the deficiency of a factor essential to the maintenance of capillary wall integrity.
BIBLIOGRAPHY

INITIAL DISTRIBUTION

**NAVY**

<table>
<thead>
<tr>
<th>Copies</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Chief, Bureau of Ships (Code 335)</td>
</tr>
<tr>
<td>1</td>
<td>Chief, Bureau of Ships (Code 320)</td>
</tr>
<tr>
<td>2</td>
<td>Chief, Bureau of Medicine and Surgery</td>
</tr>
<tr>
<td>1</td>
<td>Chief of Naval Operations (Op-07T)</td>
</tr>
<tr>
<td>1</td>
<td>Chief of Naval Research (Code 104)</td>
</tr>
<tr>
<td>3</td>
<td>Director, Naval Research Laboratory (Code 2021)</td>
</tr>
<tr>
<td>1</td>
<td>Office of Naval Research (Code 422)</td>
</tr>
<tr>
<td>1</td>
<td>Office of Naval Research (Code 441)</td>
</tr>
<tr>
<td>10</td>
<td>Office of Naval Research, FPO, New York</td>
</tr>
<tr>
<td>3</td>
<td>Naval Medical Research Institute</td>
</tr>
<tr>
<td>1</td>
<td>OIC, Radiation Exposure Evaluation Laboratory</td>
</tr>
<tr>
<td>1</td>
<td>Director, Aviation Medical Acceleration Laboratory</td>
</tr>
<tr>
<td>1</td>
<td>U. S. Naval Postgraduate School, Monterey</td>
</tr>
<tr>
<td>1</td>
<td>Commander, Naval Ordnance Laboratory, Silver Spring</td>
</tr>
<tr>
<td>1</td>
<td>Naval Missile Center (Code 5700)</td>
</tr>
<tr>
<td>1</td>
<td>U. S. Naval Hospital, San Diego</td>
</tr>
<tr>
<td>1</td>
<td>CO, Naval Medical Research Unit No. 2</td>
</tr>
<tr>
<td>1</td>
<td>CO, Naval Medical Field Research Laboratory, Camp Lejeune</td>
</tr>
</tbody>
</table>

**ARMY**

<table>
<thead>
<tr>
<th>Copies</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Chief of Research and Development (Atomic Division)</td>
</tr>
<tr>
<td>1</td>
<td>Chief of Research and Development (Life Science Division)</td>
</tr>
<tr>
<td>1</td>
<td>Deputy Chief of Staff for Military Operations (CBR)</td>
</tr>
<tr>
<td>1</td>
<td>Chief of Engineers (ENMMC-DE)</td>
</tr>
<tr>
<td>1</td>
<td>Chief of Engineers (ENGCW)</td>
</tr>
<tr>
<td>1</td>
<td>CG, Army Materiel Command (AMCRD-DE-NE)</td>
</tr>
<tr>
<td>1</td>
<td>CG, USA CBR Agency</td>
</tr>
<tr>
<td>3</td>
<td>CO, BW Laboratories</td>
</tr>
<tr>
<td>1</td>
<td>CO, Fort McClellan Alabama</td>
</tr>
<tr>
<td>1</td>
<td>Commandant, Chemical Corps Schools (Library)</td>
</tr>
<tr>
<td>1</td>
<td>CG, CBR Combat Developments Agency</td>
</tr>
<tr>
<td>1</td>
<td>CO, Chemical Research and Development Laboratories</td>
</tr>
<tr>
<td>1</td>
<td>Commander, Chemical Corps Nuclear Defense Laboratory</td>
</tr>
<tr>
<td>1</td>
<td>Eq., Army Environmental Hygiene Agency</td>
</tr>
<tr>
<td>1</td>
<td>CG., Aberdeen Proving Ground</td>
</tr>
</tbody>
</table>
CO, Army Medical Research Laboratory
Army Medical Research and Nutrition Laboratory (MEDEN-AD)
CO, Army Medical Service Combat Developments Agency
Medical Field Service School, Fort Sam Houston (Stimson Lib.)
Brooke Army Medical Center (Dept. Prev. Med.)
Director, Surgical Research Unit, Fort Sam Houston
Director, Walter Reed Army Medical Center
Hq., Army Nuclear Medicine Research Detach., Europe
CG, Combat Developments Command (CDCMR-V)
CG, Quartermaster Res. and Eng. Command
Hq., Dugway Proving Ground
The Surgeon General (MEDNE)
Office of the Surgeon General (Combat Dev.)
CG, Engineer Res. and Dev. Laboratory
Director, Office of Special Weapons Development
CG, Munitions Command
CO, Frankford Arsenal
CG, Army Missile Command

AIR FORCE

Assistant Chief of Staff, Intelligence (AFCIN-3B)
CG, Aeronautical Systems Division (ASAPRD-NS)
CO, Radiological Health Laboratory Division
Director, USAF Project RAND
Commandant, School of Aerospace Medicine, Brooks AFB
CO, School of Aviation Medicine, Gunter AFB
6571st Aeromedical Research Lab., Holloman AFB
Radiobiological Laboratory
Office of the Surgeon (SUP3.1), Strategic Air Command
Office of the Surgeon General
CG, Special Weapons Center, Kirtland AFB
Director, Air University Library, Maxwell AFB
Commander, Technical Training Wing, 3415th TTG
Hq., Second Air Force, Barksdale AFB
Commander, Electronic Systems Division (CRZT)

OTHER DOD ACTIVITIES

Chief, Defense Atomic Support Agency (Library)
Commander, FC/DASA, Sandia Base (FCDV)
Commander, FC/DASA, Sandia Base (FCTG5, Library)
Commander, FC/DASA, Sandia Base (FCWT)
Office of Civil Defense, Washington
Civil Defense Unit, Army Library
Armed Forces Institute of Pathology
Armed Services Technical Information Agency
Director, Armed Forces Radiobiology Research Institute
AEC ACTIVITIES AND OTHERS

1 Research Analysis Corporation
1 Life Science Officer, AEC, Washington
1 Director, Division of Biology and Medicine
1 NASA, Ames Research Center, Moffett Field
1 Naval Attache, Stockholm (for Commodore Troell)
1 Aerojet General, Azusa
5 Argonne Cancer Research Hospital
10 Argonne National Laboratory
2 Atomic Bomb Casualty Commission
1 AEC Scientific Representative, France
1 AEC Scientific Representative, Japan
3 Atomic Energy Commission, Washington
2 Atomic Energy of Canada, Limited
3 Atomics International
2 Battelle Memorial Institute
1 Borden Chemical Company
3 Brookhaven National Laboratory
1 Chicago Patent Group
1 Colorado State University
1 Columbia University (Rossi)
1 Committee on the Effects of Atomic Radiation
3 Defence Research Member
2 duPont Company, Aiken
1 duPont Company, Wilmington
1 Edgerton, Germeshausen and Grier, Inc., Goleta
1 Edgerton, Germeshausen and Grier, Inc., Las Vegas
2 General Dynamics, Fort Worth
2 General Electric Company, Cincinnati
8 General Electric Company, Richland
1 General Electric Company, St. Petersburg
1 General Scientific Corporation
1 Hughes Aircraft Company, Culver City
1 Iowa State University
1 Journal of Nuclear Medicine
1 Knolls Atomic Power Laboratory
2 Los Alamos Scientific Laboratory (Library)
1 Lovelace Foundation
1 Martin-Marietta Corporation
1 Massachusetts Institute of Technology
1 Mound Laboratory
1 National Academy of Sciences
2 NASA, Scientific and Technical Information Facility
1 National Bureau of Standards (Taylor)
1 National Cancer Institute
1 National Lead Company of Ohio
1 National Library of Medicine
1 New Jersey State Department of Health
New York Operations Office
New York University (Eisenbud)
Office of Assistant General Counsel for Patents
Phillips Petroleum Company
Pratt and Whitney Aircraft Division
Public Health Service, Washington
Public Health Service, Las Vegas
Public Health Service, Montgomery
Sandia Corporation, Albuquerque
Union Carbide Nuclear Company (ORGDP)
Union Carbide Nuclear Company (ORNL)
Union Carbide Nuclear Company (Paducah Plant)
United Nuclear Corporation (NDA)
U. S. Geological Survey, Denver
U. S. Geological Survey, Menlo Park
U. S. Geological Survey, Naval Gun Factory
U. S. Weather Bureau, Washington
University of California, Davis
University of California Lawrence Radiation Lab., Berkeley
University of California Lawrence Radiation Lab., Livermore
University of California, Los Angeles
University of California, San Francisco
University of Chicago Radiation Laboratory
University of Hawaii
University of Puerto Rico
University of Rochester (Atomic Energy Project)
University of Tennessee (UTA)
University of Utah
University of Washington (Donaldson)
Wayne State University
Westinghouse Electric Corporation (Rahilly)
Westinghouse Electric Corporation (NASA)
Western Reserve University (Friedell)
Technical Information Extension, Oak Ridge

USNRL

USNRL, Technical Information Division

DISTRIBUTION DATE: 8 April 1963
Naval Radiological Defense Laboratory
USNRDL-TR-628

Differential response to allogenic and xenogenic skin grafts by sublethally irradiated (670 rad) and non-irradiated mice sensitized by various means by M. L. Tyan and L. J. Cole 11 March 1963 26 p. tables 13 refs. UNCLASSIFIED

Twelve to 14 week old female LAF1 mice were pre-sensitized either with 3 i.p. injections of BALB/c or rat spleen or skin cells, or by means of two consecutive BALB/c or rat skin tail grafts. One week following the last injection or the rejection of the second skin graft, the mice either were grafted with LAF1, BALB/c, C3D/2 and rat skin or they received 670 rad whole body X radiation and were grafted immediately thereafter. The data indicate that skin grafts induce a more vigorous and more radioresistant "second-set" response than do dissociated cells. Pre-sensitization with allogenic spleen cells resulted in prolonged survival of subsequent allogenic skin grafts in sublethally irradiated mice. The second-set response to a xenogenic skin graft was found to be more radioresistant than that to an allogenic graft. The converse was true with regard to the first-set response.